TOP TEN perturbations for 38567_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38567_at
Selected probe(set): 205789_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38567_at (205789_at) across 6674 perturbations tested by GENEVESTIGATOR:
IL-4; GM-CSF study 1 (late) / untreated monocyte sample
Relative Expression (log2-ratio):-5.36617Number of Samples:6 / 12
Experimental | IL-4; GM-CSF study 1 (late) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. | |
Control | untreated monocyte sample |
Freshly isolated human monocytes from healthy donors. |
Langerhans cell histiocytosis study 1 / normal myeloid dendritic cell sample
Relative Expression (log2-ratio):-5.0800886Number of Samples:7 / 3
Experimental | Langerhans cell histiocytosis study 1 |
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
Control | normal myeloid dendritic cell sample |
Normal myeloid dendritic cells were isolated from peripheral blood of healthy adult donors. Myeloid dendritic cells were defined as HLA-DR+ / CD11c + / BDCA1+ / BDCA3- population. |
human AB serum study 1 (late) / IL-4; GM-CSF study 1 (late)
Relative Expression (log2-ratio):4.6869164Number of Samples:3 / 6
Experimental | human AB serum study 1 (late) |
Monocytes, cultured in RPMI medium containing 10% human AB serum (HS) instead of FBS, and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. | |
Control | IL-4; GM-CSF study 1 (late) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. |
IL-4; GM-CSF study 1 (early) / untreated monocyte sample
Relative Expression (log2-ratio):-4.658284Number of Samples:6 / 12
Experimental | IL-4; GM-CSF study 1 (early) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 6 hours. | |
Control | untreated monocyte sample |
Freshly isolated human monocytes from healthy donors. |
human AB serum study 1 (intermediate) / IL-4; GM-CSF study 1 (intermediate)
Relative Expression (log2-ratio):4.47843Number of Samples:3 / 7
Experimental | human AB serum study 1 (intermediate) |
Monocytes, cultured in RPMI medium containing 10% human AB serum (HS) instead of FBS, and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours. | |
Control | IL-4; GM-CSF study 1 (intermediate) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours. |
AM580 study 1 / vehicle (DMSO/EtOH)/ IL-4/ GM-CSF treated monocyte sample
Relative Expression (log2-ratio):4.391239Number of Samples:3 / 3
Experimental | AM580 study 1 |
Monocytes were cultured for 5 days with 500 U/ml IL-4 and 800 U/ml GM-CSF, cytokine treatment was repeated at day 3. AM580 (AM; 100 nM) was added at the beginning of differentiation. ATC code:--- | |
Control | vehicle (DMSO/EtOH)/ IL-4/ GM-CSF treated monocyte sample |
Monocytes were cultured for 5 days with 500 U/ml IL-4 and 800 U/ml GM-CSF, cytokine treatment was repeated at day 3. Vehicle (DMSO/ethanol) was added at the beginning of differentiation. |
IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample
Relative Expression (log2-ratio):-4.1860943Number of Samples:7 / 12
Experimental | IL-4; GM-CSF study 1 (intermediate) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours. | |
Control | untreated monocyte sample |
Freshly isolated human monocytes from healthy donors. |
Hep-G2 / HepaRG
Relative Expression (log2-ratio):-4.12183Number of Samples:9 / 12
Experimental | Hep-G2 |
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: | |
Control | HepaRG |
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
stem cell differentiation study 46 (BMP4, inhibitors) / stem cell differentiation study 46 (BMP4)
Relative Expression (log2-ratio):-3.8150282Number of Samples:3 / 3
Experimental | stem cell differentiation study 46 (BMP4, inhibitors) |
Extraembryonic cells differentiated from WA09 cells in chemically defined medium supplemented with BMP4 and inhibitors of activin and FGF2. Differentiation was performed in the absence of feeders cells and serum. Cells were first grown on fibronection-coated plates in CDM supplemented with activin (10 ng/ml) and FGF2 (12 ng/ml) for two days and then in CDM supplemented with BMP4 (10 ng/ml), an inhibitor of Alk4/5/7 receptors (type I Activin receptor-like kinase), SB431542 (10uM), and an inhibitor of FGF receptors, SU5402 (10uM), for 3-4 days. | |
Control | stem cell differentiation study 46 (BMP4) |
Mesendoderm cells differentiated from WA09 cells in chemically defined medium (CDM) supplemented with BMP4. Differentiation was performed in the absence of feeders cells and serum. Cells were first grown on fibronection-coated plates in CDM supplemented with activin (10 ng/ml) and FGF2 (12 ng/ml) for two days and then in CDM supplemented with BMP4 (10 ng/ml) for 3-4 days. |
colorectal adenoma study 7 (colonic crypt) / adjacent colonic crypt epithelial cell sample
Relative Expression (log2-ratio):-3.554894Number of Samples:5 / 5
Experimental | colorectal adenoma study 7 (colonic crypt) |
Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal adenoma. | |
Control | adjacent colonic crypt epithelial cell sample |
Adjacent colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from patients with colorectal cancer. |